Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
OVAS's Cash to Debt is ranked higher than
97% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. OVAS: No Debt )
OVAS' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
OVAS's Interest Coverage is ranked higher than
80% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OVAS: No Debt )
OVAS' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 41.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -64.16
OVAS's ROE (%) is ranked higher than
64% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. OVAS: -64.16 )
OVAS' s 10-Year ROE (%) Range
Min: -95.33   Max: -80.21
Current: -64.16

-95.33
-80.21
ROA (%) -58.66
OVAS's ROA (%) is ranked higher than
61% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. OVAS: -58.66 )
OVAS' s 10-Year ROA (%) Range
Min: -72.29   Max: -72.25
Current: -58.66

-72.29
-72.25
ROC (Joel Greenblatt) (%) -2598.22
OVAS's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. OVAS: -2598.22 )
OVAS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3579.1   Max: -3561.61
Current: -2598.22

-3579.1
-3561.61
» OVAS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OVAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.30
OVAS's P/B is ranked higher than
66% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. OVAS: 9.30 )
OVAS' s 10-Year P/B Range
Min: 0   Max: 9.3
Current: 9.3

0
9.3
EV-to-EBIT -13.98
OVAS's EV-to-EBIT is ranked higher than
85% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. OVAS: -13.98 )
OVAS' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -13.98

Current Ratio 8.36
OVAS's Current Ratio is ranked higher than
84% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. OVAS: 8.36 )
OVAS' s 10-Year Current Ratio Range
Min: 7.81   Max: 30.5
Current: 8.36

7.81
30.5
Quick Ratio 8.36
OVAS's Quick Ratio is ranked higher than
85% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. OVAS: 8.36 )
OVAS' s 10-Year Quick Ratio Range
Min: 7.81   Max: 30.5
Current: 8.36

7.81
30.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.09
OVAS's Price/Net Cash is ranked higher than
83% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. OVAS: 10.09 )
OVAS' s 10-Year Price/Net Cash Range
Min: 2.51   Max: 6.4
Current: 10.09

2.51
6.4
Price/Net Current Asset Value 10.09
OVAS's Price/Net Current Asset Value is ranked higher than
81% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. OVAS: 10.09 )
OVAS' s 10-Year Price/Net Current Asset Value Range
Min: 2.51   Max: 6.4
Current: 10.09

2.51
6.4
Price/Tangible Book 9.30
OVAS's Price/Tangible Book is ranked higher than
73% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. OVAS: 9.30 )
OVAS' s 10-Year Price/Tangible Book Range
Min: 2.42   Max: 5.9
Current: 9.3

2.42
5.9
Earnings Yield (Greenblatt) -7.20
OVAS's Earnings Yield (Greenblatt) is ranked higher than
71% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. OVAS: -7.20 )
OVAS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -8.2   Max: 0
Current: -7.2

-8.2
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
OvaScience, Inc. was established in 2011 & is based in Cambridge, Massachusetts. The Company is a life science company developing proprietary products to improve the treatment of female infertility based on recent scientific discoveries about the existence of egg precursor cells. The Company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011.
» More Articles for OVAS

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: CLMS, OPK, OVAS, RTRX, MDCA Mar 17 2014 

More From Our Partners
How to Uncover Institutional Buying - Screen of the Week Nov 18 2014 - ZACKS

More From Other Websites
OvaScience to Participate in Fortune Most Powerful Women Next Gen Conference Nov 26 2014
ProQR Therapeutics Announces Results for the Third Quarter of 2014 Nov 24 2014
OVASCIENCE, INC. Financials Nov 18 2014
OvaScience to Participate in Partnering for Cures Conference Nov 11 2014
OvaScience misses 3Q profit forecasts Nov 10 2014
OvaScience misses 3Q profit forecasts Nov 10 2014
OVASCIENCE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 10 2014
OvaScience Reports Third Quarter 2014 Financial Results Nov 10 2014
Will OvaScience (OVAS) Continue to Surge Higher? Oct 24 2014
OvaScience downgraded by Oppenheimer Oct 08 2014
Why You Shouldn't Bet Against OvaScience (OVAS) Stock Sep 23 2014
OvaScience CEO Michelle Dipp Named Outstanding Young Leader Sep 18 2014
OVASCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Sep 18 2014
OvaScience Appoints Jeffrey Young to Chief Financial Officer Sep 18 2014
Earnings Estimates Moving Higher for OvaScience (OVAS): Time to Buy? Sep 10 2014
OvaScience to Present at the Rodman & Renshaw/H.C. Wainwright Annual Global Investment Conference Sep 03 2014
OvaScience (OVAS) Shows Strength: Stock Up 7% Aug 12 2014
OvaScience Reports Second Quarter 2014 Financial Results Aug 07 2014
OVASCIENCE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 07 2014
OvaScience to Present at the Wedbush Life Sciences Management Access Conference Aug 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK